The Immune Thrombocytopenic Market is Expected to Grow Due to Factors like Increase in the Patient Pool and Expected Entry of Emerging Therapies

DelveInsight's "Immune Thrombocytopenic Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of ITP historical and forecasted epidemiology as well as the ITP market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

Latest Developmental Activities in the Immune Thrombocytopenic Treatment Landscape

• BT-595 (IgG Next Generation) by Biotest is an intravenously administered, novel polyvalent immunoglobulins (IVIG) designed to specifically to treat primary immune deficiencies, secondary antibody deficiency syndromes, and several autoimmune disorders. IgG Next Generation is manufactured using an innovative production process and will be the master product of the newBiotest Next Level manufacturing facility. In April 2022, Biotest submitted marketing authorization application for IgG Next Generation in Germany.

• Efgartigimod (ARGX-113) by Argenx is an investigational therapy for ITP and was designed to exploit the natural interaction between IgG antibodies and the recycling receptor FcRn. The company has designed efgartigimod to degrade circulating disease-causing autoimmune antibodies and has potential in many large and orphan indications namely multiple sclerosis, immune thrombocytopenia, systemic lupus erythematosus, myasthenia gravis and skin blistering diseases. The company is evaluating the drug in Phase III trials for the treatment of ITP patients.

• Rilzabrutinib (PRN-1008) is an orally administered reversible covalent inhibitor of Bruton Tyrosine Kinase (BTK). BTK is an essential signaling element downstream of the B cell receptor (BCR), Fc-gamma receptor, and Fc-epsilon receptor pathways. BTK activation is critical for B cell activation and maturation. BTK also regulates antibody-mediated activation of other immune cells, such as macrophages, neutrophils, and mast cells through Fc receptor signaling. The drug candidate is a fast-acting, orally available therapy that could effectively and safely modulate B-cell function without depleting the B-cells and is expected to be a major advancement in treating autoimmune and inflammatory diseases. Rilzabrutinib is currently in the Phase III stage of development to treat ITP in adults and adolescent. Rilzabrutinib has been granted ODD and FTD by the US FDA for the treatment of ITP.

• In June 2022, Sanofi presented the efficacy and adverse events data from a phase I/II trial in Idiopathic thrombocytopenic purpura at the 27th Congress of the European Haematology Association (EHA-2022).

• In April 2022, Biotest submitted a marketing authorization application for IgG Next Generation in Germany.

Explore more information on the latest breakthroughs in the Immune Thrombocytopenic Treatment Landscape @ Immune Thrombocytopenic Market Size- https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Immune Thrombocytopenic Overview

Immune thrombocytopenia (ITP), previously called immune thrombocytopenic purpura or idiopathicthrombocytopenic purpura, is an autoimmune disorder that occurs when the body attacks its own platelets and destroys them too quickly.

Key Takeaways from the Immune Thrombocytopenic Market Report

• The market size of Immune thrombocytopenia in the 7MM was ~USD 3,100 million in 2021.

• According to the assessment done by DelveInsight, the estimated total immune thrombocytopenia prevalent cases in the 7MM were approximately 184K in 2021.

• The leading immune thrombocytopenia companies include UCB Biopharma, Sanofi, Principia Biopharma, Argenx, Millennium Pharmaceuticals, Takeda, Biotest, GC Pharma, UCB, HanAll Biopharma, Immunovant, Momenta Pharmaceuticals, Hutchison MediPharma, Cour Pharmaceutical Development, and others.

• The promising immune thrombocytopenia pipeline therapies include Rilzabrutinib (PRN-1008), Efgartigimod (ARGX-113), BIVV020, TAK-079, BT-595, GC5101B (GC5107A, IV-Globulin SN Inj. 10%), Rozanolixizumab, and others

Immune thrombocytopenia Epidemiology Segmentation in the 7MM
• Total Immune Thrombocytopenic Prevalent Population
• Total Immune Thrombocytopenic Diagnosed Prevalent Population
• Immune Thrombocytopenic Gender-specific Diagnosed Prevalence

Download the report to understand which factors are driving immune thrombocytopenia epidemiology trends @ Immune Thrombocytopenia Epidemiological Insights- https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Immune Thrombocytopenia Treatment Market
First-line treatment options include corticosteroids, intravenous immunoglobulin (IVIg), and intravenous anti-Dimmunoglobulin (the latter only for non-splenectomized Rhesus-D positive patients). Patients who fail to respond orwho relapse face the options of treatment with second-line drug therapy or splenectomy but there is no clearevidence to support the best approach. Splenectomy can provide long term efficacy in around 60% of cases. Secondline drug therapies include high dose dexamethasone or methylprednisolone, high-dose IVIg or anti-D Ig, vincaalkaloids, and danazol, the immunosuppressants cyclophosphamide, azathioprine, and cyclosporine ormycophenolate mofetil, and the anti-CD-20 monoclonal antibody rituximab.

Immune Thrombocytopenia Market Insights
The market of ITP is anticipated to change during the forecasted period owing to the expected launch of emerging therapies. There are many pipeline therapies under development for the treatment of the patient with ITP. The emerging therapies for the treatment of ITP include BT595, ARGX-113, Rilzabrutinib (PRN-1008), and others. ITP is a disease with an unknown cause. Some agents or a combination of agents -- bacteria, viruses, and antigens --trigger the body's immune system to produce an inflammatory reaction in the intestinal tract. Although the cause of ITP remains unknown, considerable progress has been made in recent years to unravel the pathogenesis of this disease.

Find out more about the Immune Thrombocytopenic Pipeline Segmentation, Therapeutics Assessment, and Immune Thrombocytopenic Emerging Drugs @ Immune Thrombocytopenic Treatment Landscape- https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Immune Thrombocytopenic Market Report

• Coverage- 7MM

• Immune Thrombocytopenic Companies- UCB Biopharma, Sanofi, Principia Biopharma, Argenx, Millennium Pharmaceuticals, Takeda, Biotest, GC Pharma, UCB, HanAll Biopharma, Immunovant, Momenta Pharmaceuticals, Hutchison MediPharma, Cour Pharmaceutical Development, and others.

• Immune Thrombocytopenic Pipeline therapies- Rilzabrutinib (PRN-1008), Efgartigimod (ARGX-113), BIVV020, TAK-079, BT-595, GC5101B (GC5107A, IV-Globulin SN Inj. 10%), Rozanolixizumab, and others.

• Immune Thrombocytopenic Market Dynamics: Immune Thrombocytopenic Market Drivers and Barriers

• Immune Thrombocytopenic Market Access and Reimbursement, Unmet Needs

Dive deep into rich insights for drugs for Immune Thrombocytopenic Pipeline Companies and Therapies, click here @ Immune Thrombocytopenic Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Immune Thrombocytopenic Purpura (ITP) Market Overview at a Glance
4. Executive Summary of Immune Thrombocytopenic Purpura (ITP)
5. Key events
6. Disease Background and Overview
7. Treatment of ITP
8. Methodology
9. Epidemiology and Patient Population
10. Patient Journey
11. Marketed Products
12. Emerging Therapies
13. ITP Seven Major Market Analysis
14. Attribute Analysis
15. Market Access and Reimbursement
16. KOL Views
17. Unmet Needs
18. SWOT Analysis
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

Got Queries? Find out the related information on Immune Thrombocytopenic Mergers and acquisitions, Immune Thrombocytopenic Licensing Activities @ Immune Thrombocytopenic Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/immune-thrombocytopenia-itp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.